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Breast cancer comprises approximately 
13 .9% of all cases of malignancy in both sexes 
and 19% in women, in whom it is the common-
est form of cancer . 1 The American Cancer So-
ciety estimates that 11 0,000 women developed 
breast cancer in 1 981 , and some 3 7, 1 00 
deaths from the disease occurred. ~ The five-
year survival rate has been improving over the 
past 40 years as shown in Table 11 , but pa-
tients remain in risk of recurrence indefinitely, 
and survival for ten years is generally accepted 
as the minimal time period necessary to estab-
lish the validity of new therapies. 
Data from the first study of the National 
Surgical Adjuvant Breast and Bowel Project 
(NSABP) are shown in Table 2 and indicate that 
the majority of women with breast cancer ulti-
mately succump to the di$ease.3 Thus, although 
only 1 0% of cases present with metastatic dis-
ease (an additional 5% predictably have very 
rapid progression : inflammatory carcinoma, ex-
tensive local or regional disease), over half of 
those undergoing mastectomy will develop re-
currence within ten years. 
The identification of women with either ad-
verse or favorable prognostic features modifies 
these figures considerably. Among the impor-
tant favorable variables are : attainment of 
menopausal status for at least five years ; in-
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creasing age; primary tumors two cm in diame-
ter or less; absence of regional node in-
volvement ; estrogen and progesterone receptor 
positivity and , for estrogen receptors at least , 
absolute amount of receptor; delay between ini-
tial presentation and recurrence; skin or nodal 
local recurrence as opposed to visceral metas-
tasis; and perhaps most important, an overall 
less aggressive biological character of the tu-
mor. 
Adverse prognostic features include: a 
clinical picture of inflammatory carcinoma; con-
current pregnancy; liver metastasis; multiple vis-
ceral metastases at presentation ; brain, men-
ingeal, epidural involvement, or spinal cord 
compression secondary to vertebral collapse; 
lymphangitic pulmonary spread; absence of es-
trogen and, possibly, progesterone receptor; 
failure of previous therapy for systemic disease; 
and inability to withstand the toxicities associ-
ated with chemotherapy or hormonal therapy. 
An excellent review of all phases of breast can-
cer has recently been published .5 
I intend to concentrate on four areas in 
greater detail : 1) the usefulness of receptor as-
says in predicting the response to therapy; 2) 
chemotherapy of advanced metastatic disease; 
3) adjuvant chemotherapy following surgery; 4) 
the usefulness of antiestrogens in hormonally-
responsive disease. 
Receptor Assays 
Steroid hormones are known to act by 
crossing the cell membrane where they bind to 
specific cytoplasmic receptors . The receptor-
steroid complex is activated and translocates to 
the nucleus where it interacts with chromatin. 
TABLE 1 
Five-Year Survival Rates In Breast Cancer 
1940-1949 
1953-1959 
1960-1964 
1965-1969 
53% 
60% 
62% 
64% 
(Note: Adapted from Cutler SJ, Myers, MH, Green SB: 
Trends in survival rates of patients with cancer. N Engl J 
Med 293: 122-124, 1975.) (By Permission) 
As a result of this interaction, RNA synthesis is 
increased and new proteins are synthesized.6 It 
now seems that the appearance of progester-
one receptors in breast tumors is the result of 
estrogen stimulation and is a measure of hor-
monal responsiveness (Table 3). 7 
The presence of estrogen receptor (ER) is 
an important determinant of prognosis inde-
pendent of the effects of age, nodal in-
volvement and primary lesion size (Table 4). 
The ER level is less in the tumors of younger 
women and is less in primary as opposed to 
metastatic tumor (Table 5). 7 
Estrogen receptor positivity successfully 
predicts objective responses to hormonal ther-
apy (Table 6) to the extent that only ER+ pa-
tients should be treated initially with ablation or 
hormone administration. 7·8 It is of interest that 
the perimenopausal patient, classically not re-
sponsive to hormonal therapy, tends to have 
lower ER positivity than either the premeno-
pausal or postmenopausal (five years or more) 
patient. Clearly the traditional treatment deci-
sion based on premenopausal or post-
menopausal status alone must be modified to 
include ER status. 
TABLE 2 
Results of Surgical Treatment Alone 
Ten-Year 
Treatment Ten-Year 
Failure Rate 
Negative nodes 24% 
Positive nodes: 
1- 3 65% 
4 or more 86% 
All 76% 
All patients 50% 
(Note: Adapted from the first NSABP Protocol) 
(By Permission) 
Survival 
65% 
38% 
13% 
25% 
46% 
TABLE 3 
Objective Response to Endocrine Therapy 
No. Responding/ 
Estrogen-Receptor Negative/ 
Progesterone-Receptor 
Negative 
Estrogen-Receptor Positive/ 
Progesterone-Receptor 
Positive 
No. % 
Evaluable Response 
9/ 63 14% 
67 / 91 74% 
(Note: Adapted from McGuire WL: Hormone receptors: 
Their role in predicting prognosis and response to endo-
crine therapy. Semin Oncol 5: 428-433 , 1978) 
(By Permission) 
Chemotherapy of Advanced Breast Cancer 
A large number of chemotherapeutic 
drugs have been shown to produce objective 
responses defined as partial and complete re-
sponses (Table 7). Table 8 lists a number of the 
commonly used agents and responses. The 
early studies of Greenspan and others sug-
gested that combination therapy was consid-
erably more effective, and therefore the initial 
chemotherapeutic treatment is almost always a 
combination, most commonly Cytoxan-Metho-
trexate-5-fluorouracil (CMF). The CMF combina-
tion shown in Table 9 is based on an Eastern 
Cooperative Oncology Group (ECOG) protocol 
with 49 /93 patients responding. Complete re-
sponses lasted a median of eight or more 
months, partial responses four to eight months. 
Many oncologists, including myself, use less 
Methotrexate, 30-40 mgm/M2 , and one series 
TABLE 4 
Estrogen Receptor and the Prognosis for Early 
Recurrence of Breast Cancer 
Category 
Age: 
Less than 50 
Over 50 
Nodes involved: 
0 
1-3 
4 or more 
Size of primary: 
Less than 2 cm 
Greater than 2 cm 
Recurrence at 18 months(%) 
Estrogen- Estrogen-
Receptor Receptor 
Negative Positive 
34 14 
35 8 
12 6 .5 
38 12.5 
62 27.0 
33 0 
31 14 
(Note: Adapted from Table 1, McGuire WL: Semin Oncol 5: 
428, 1978, and Knight WA, et al: Cancer Res 37 : 4669, 
1 9 77 .) (By Permlaslon) 
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TABLE 5 
Distribution of Estrogen Receptor in Primary and Metastatic Breast Cancer 
Primary Biopsy Metastatic Biopsy 
Age: Under50 50 or over Under 50 50 or over 
ER level : 
Under 3 37% 23% 52% 31% 
3-10 20% 15% 14% 16% 
11-1 00 41% 36% 29% 27% 
101-2000 2% 20% 5% 20% 
(Note: Taken from Table 2, McGuire WL: Semin Oneal 5: 429, 1978.) (By Permission) 
showed a 62% respon$e rate with CMF using 
Methotrexate at 40 mgm/M 2 . 
There is no doubt that the single most ef-
fective drug is doxorubicin hydrochloride (Adria-
mycin(R)) with reported response rates of up to 
45%. Combinations using Adriamycin also show 
a higher response rate than CMF or CMFP 
(See Table 9), and some oncologists use CAF 
as the initial treatment. It is, however, desirable to 
have a combination available for use after the 
initial treatment fails, and we have tended to 
reserve Adriamycin for wse in relapse, usually 
combining it with the vinca alkaloid, vincristine. 4 
An exception to this sequence is the pre-
menopausal, ER- patient with extensive vis-
ceral and bone disease. These women usually 
have very rapid, progressive disease, and initial 
treatment with CAF is warranted in an attempt 
to obtain even a small measure of control of 
their disease. 
An additional consideration is the treat-
ment of the ER+ patient with, combined hor-
monal and chemical therapy. Only some 10-
20% of objective responses are complete re-
sponses, but patients achieving complete re-
sponses tend to have longer remissions and 
better survival. Moreover, a small number may 
be curable since the achievement of complete 
response in large numbers of patients has been 
associated historically with the development of 
very long-term survival or cure. Thus attempts 
to increase the number of patients achieving 
complete response and to maintain those in 
complete response for as long as possible are 
now the subject of intense study. 
Legha and his colleagues at the M. D. An-
derson Hospital and Tumor Institute recently re-
ported on 11 6 patients with breast cancer 
achieving complete remission . A marked im-
provement in the number in complete response 
and the duration of complete response was 
seen in premenopausal patients who underwent 
TABLE 6 
Objective Response by Therapy and Estrogen .Receptor 
Therapy 
Ablative Surgery: 
Adrenalectomy 
Oophorectomy 
Hypophysectomy 
Total 
Hormonal Therapy: 
Androgens 
Estrogens 
Glucocorticoid 
Total 
Antiestrogens: 
Nafoxidine 
Tamoxifen 
Total 
ER+ 
#% 
40 / 76 (53%) 
28/43 (65%) 
9/14 (64%) 
77 / 133(58%) 
10/28 (36%) 
38 / 60 (63%) 
15 / 32 (47%) 
63 / 1 20(53%) 
12 / 17 (71%) 
18 / 40 (45%) 
30 / 57 (53%) 
Objective Response/ Evaluable Patients 
ER - Pre-ER patients 
# % (All comers) 
4 / 41 (10%) 28% 
2/74 ( 3%) 29% 
0/12 ( 0%) 33% 
6/ 127( 5%) 
2/22 ( 9%) 
2/ 49 ( 4%) 
0/ 19 ( 0%) 
4 / 90 ( 4%) 
0/ 16 ( 0%) 
0/ 15 ( 0%) 
0/ 31 ( 0%) 
18% 
36% 
29% 
33% 
(Note : Adapted from Table 2, Legha SS et al : Ann Intern Med 88: 69, 1978, and Table 4 , Carbone PP , Davis TE: Semin Oneal 
5: 417, 1978.) (By Permission) 
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TABLE 7 
Tumor Response 
Complete Remission No clinical evidence of active 
Complete Response 
Partial Response 
Stable Disease 
Progressive Disease 
tumor; no subjective evidence 
of disease 
All measurable disease disappears 
50% or greater reduction in mea-
surable tumor in the absence of 
progression or recurrence of 
new lesions elsewhere 
Steady state or response less than 
50% reduction in measurable 
tumor. No increase in size of 
any lesion or appearance of 
new lesions 
Occurrence of any new lesion or 
increase of any measurable 
lesion> 50%, even in the face 
of regressing lesions 
elsewhere 
(Note. Adapted from Carter SK: The design of clinical trials 
in cancer therapy (ed M Staquet) Brussels: Editions Scien-
tifiques Europeennes, 1972.) (By Permission) 
oophorectomy and received chemotherapy im-
mediately compared to women receiving che-
motherapy when disease progression oc-
curred. 9 
An earlier study of adrenalectomy, oopho-
rectomy and chemotherapy by Hoge et al re-
vealed a much higher objective response rate 
(80%) when compared to chemotherapy or hor-
monal ablation alone. 10 These and other studies 
suggest that attempts to increase the number of 
patients in complete response by combined 
therapy may be worthwhile. However , such 
studies remain research protocols, and much 
longer observation will be necessary to assess 
their true value. 
Adjuvant Chemotherapy 
The large number of patients failing to 
achieve cure following radical mastectomy sug-
TABLE 8 
Summary of Single Agents Active Against Advanced Breast Cancer 
No. Evaluable No. Objective Response 
Drug Patients Responses (%) 
Alkylating agents: 
Cyclophosphamide 529 182 34 
Nitrogen mustard 92 32 35 
Phenylalanine mustard 86 20 23 
Chlorambucil 54 11 20 
Thio-TEPA 162 48 30 
Antimetabolites: 
5-Fluorouracil 1263 324 26 
Methotrexate 356 120 34 
6-Mercaptopurine 45 6 13 
Arabinosyl cytosine 64 6 9 
Vinca Alkaloids: 
Vincristine 226 47 21 
Vinblastine 95 19 20 
Antibiotics: 
Actinomycin D 44 5 11 
Adriamycin 193 67 35 
Bleomycin 8 0 0 
Mithramycin 32 5 16 
Mitomycin 60 23 38 
Miscellaneous agents: 
Hydroxyurea 21 4 19 
BCNU 76 16 21 
CCNU 155 18 12 
Methyl CCNU 33 2 6 
Hexamethylmelamine 39 11 28 
lmidazole carboxamide 29 2 7 
Procarbazine 21 5 
(Note: Compiled by Susan J. Mellette, MD, Professor of Medicine, Medical College of Virginia .) 
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Regimen 
CMFVP 
CMF 
CMFP 
AV 
CA 
CAF 
DAV 
TABLE 9 
Useful Drug Combinations In the Treatment of Breast Cancer 
Drug Dosage and Schedule 
Cyclophosphamide 80 mg / m2 p.o. daily 
Methotrexate 20 mg / m2 i.v . weekly 
Fluorouracil 500 mg / m2 i.v. weekly 
Vincristine 1 .0 mg / m2 p.o. daily x 15 (then taper) ! 
Cyclophosphamide 100 mg / m2 p.o. days 1-14 
Methotrexate 60 mg / m2 i. v. days 1 & 8 
5-Fluorouracil 600 mg / m2 i.v. days 1 & 8 
(repeat cycles every 4 weeks) 
Cyclophosphamide 1 00 mg / m2 p.o . days 1-14 
Methotrexate 60 mg / m2 i. v. days 1 & 8 
5-Fluorouracil 600 mg / m2 i.v. days 1 & 8 
Prednisone 40 mg / m2 p.o. days 1-14 
(repeat cycles every 4 weeks) 
Adriamycin 75 mg / m2 i.v. day 1 
Vincristine 1 .4 mg / m2 i.v. day 1 & 8 
(repeat cycles every 3 weeks) 
Cyclophosphamide 200 mg / m2 p.o. days 3-6 
Adriamycin 40 mg / m2 i.v. day 1 
(repeat cycles every 3-4 weeks) 
Cyclophosphamide 100 mg / m2 p.o . days 1-14 
Adriamycin 30 mg / m2 i.v . days 1 & 8 
Fluorouracil 500 mg / m2 i.v. days 1 & 8 
(repeat cycles every 4 weeks) 
Dibromodulcitol 150 mg / m2 p.o . days 1-10 
Adriamycin 45 mg / m2 i.v . day 1 
Vincristine 1 .2 mg / m2 i.v . day 1 
(repeat cycles every 4 weeks) 
(Note: From Table 3 . Carbone PP, Davis TE : Semin Onco/ 5:417 , 1978.) (By Permission) 
Response Rate(%) 
62 
53 
63 
52 
74 
82 
71 
gests that breast cancer is in fact a systemic 
disease at a very early stage, if not at its onset. 
There is increasing evidence to support a multi-
centric origin for many tumors including breast 
cancer, and it is now apparent that very large 
numbers of cells are shed systemically by even 
small cancers. Moreover, surgical failure results 
in local recurrence in only about 15% of cases, 
and most of these patients eventually show dis-
semination at other sites. 4 Adjuvant chemother-
apy given after surgery is designed to destroy 
disseminated tumor cells and increase the likeli-
hood of cure. 
Two major groups have studies in prog-
ress: the National Surgical Adjuvant Breast Proj-
ect (NSABP) and the National Tumor Institute in 
Milan. 11 · 12 • 13 The initial NSABP trial used a 
single drug , L-phenylalanine mustard, and the 
first Milan study used CMF for 12 cycles. Bene-
fit was seen in premenopausal patients with one 
to three nodes involved in both series and for 
four or more nodes in the Milan series. Tables 
1 OA and 1 OB show data updated to four years 
as of May 1 9 7 8 and represent the most recent 
comparative data. No benefit to premenopausal 
women without nodal involvement has been 
demonstrated . The situation for post-
menopausal women is less certain at present 
because the Milan study is reported to show 
benefit for the woman with four or more nodes 
who is able to take 85% or more of the sched-
uled adjuvant chemotherapy. 13 The NSABP 
data do not show benefit . Therefore adjuvant 
therapy should be reserved for premenopausal 
women with one or more positive axillary nodes. 
To date, a clear-cut advantage for three drugs 
and for the duration of treatment has not been 
established, although treatment for six months 
and 1 2 months does not appear much different 
at the present.1 4 
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Antiestrogens 
A number of steroidal and non-steroidal 
compounds have antiestrogenic effects. Most 
clinical trials have employed the nonsteroidal 
compounds nafoxidine and tamoxifen . The lat-
TABLE 10 
A. Comparison of NSABP /Milan Data 
-Control Patients-
Age/ Positive 
Menopause Nodes 
All Pts. All 
All Pts. 1-3 
All Pts. 4 
49 / Pre- All 
50/ Post- All 
49 / Pre- 1-3 
49 / Pre- 4 
50/ Post- 1-3 
50/ Post- 4 
% Disease Free 
at Four Years 
NSABP Milan 
51 47 
63 54 
40 32 
43 41 
56 52 
54 49 
35 23 
67 58 
43 42 
5/ 78 
B. Comparison of NSABP /Miian Data 
-Treated Patients-
Age/ Positive 
Menopause Nodes 
All Pts. All 
All Pts. 1-3 
All Pts. 4 
49 / Pre- All 
50 / Post- All 
49 / Pre- 1-3 
49 / Pre- 4 
50 / Post- 1- 3 
50 / Post- 4 
% Disease Free 
at Four Years 
NSABP Milan 
59 66 
74 74 
40 49 
65 75 
56 56 
86 87 
40 51 
68 61 
40 1 45 
5 / 78 
-
(Note: Courtesy of Dr. Bernard Fisher and the National Surgical Adjuvant Breast Project.) 
ter is commercially available and is believed to 
bind to the estrogen receptor in the cytosol , 
translocate to the nucleus, and bind to chroma-
tin but not release easily. Cytoplasmic receptors 
also are depleted after tamoxifen therapy. It is 
clear that the effectiveness of antiestrogenic 
treatment correlates very well with estrogen-re-
ceptor positivity. An overall response rate of 
about 33% is seen, but the rate in ER+, post-
menopausal patients is as high as 60%. 15 This 
is similar to the percentage of tamoxifen re-
sponse in patients previously responding to hor-
monal therapy. Patients failing to respond to 
hormonal therapy usually do not respond to ta-
moxifen. 
Most studies have been done in post-
menopausal patients, but benefit in pre-
menopausal patients has not been excluded. 
The dose is 1 0 mgm by mouth twice a day and 
is usually tolerated well . Nausea and vomiting 
are seen in some patients (12% in one series), 
hot flushes in about 21 %, hypercalcemia occa-
sionally, and mild platelet count depression 
rarely. 
Synthesis 
The management of the patient with 
breast cancer increasingly depends on careful 
staging taking into account the major prognos-
tic features outlined above. The patient _with lo-
calized disease, small primary and no axillary 
nodes is probably best served at present by 
modified radical mastectomy or radical mastec-
tomy, although studies in progress at a large 
number of centers are beginning to suggest that 
less extensive surgery with radiation therapy to 
the chest wall and nodes may be useful in se-
lected cases. Knowledge of the presence or ab-
sence of axillary node metastasis and the num-
ber of nodes involved is of such central 
importance to prognosis that procedures which 
do not provide this information cannot be con-
sidered useful at this time. 
Premenopausal patients with one or more 
positive nodes but without evidence of meta-
static disease elsewhere should be considered 
candidates for adjuvant therapy. However, the 
question of whether adjuvant cytotoxic chemo-
therapy, immunotherapy, or hormonal therapy 
should be given and for how long remains in the 
investigative stage. Adjuvant chemotherapy 
with CMF cannot be considered of proven value 
for the general population of patients, and every 
effort should be made to include these patients 
in clinical trials to establish the value of adjuvant 
therapy. 
The choice of therapy for the patient with 
extensive disease also has become more com-
plex. ER+ patients of advanced age with cuta-
neous, pleural , nodal, early bone, or nodular 
pulmonary disease may respond well to estro-
gen administration , and on re-exacerbation , 
androgen or prednisone. Approximately 25% of 
these patients will show regression of the tumor 
when estrogen is stopped-the "rebound" 
phenomenon, which has also been described 
after androgen and tamoxifen therapy. 
The premenopausal , ER+ patient cur-
rently is treated with oophorectomy initially and , 
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TABLE 11 
Metastatic Disease 
Premenopausal Postmenopausal 
ER+ ER- ER- ER+ 
Oophorectomy Chemotherapy Estrogen 
Medical adrenalectomy 
Surgical adrenalectomy 
Antiestrogen 
Chemotherapy 
upon relapse, adrenalectomy or hypophysec-
tomy. In a series studied at the Medical College 
\ of Virginia, 16 medical adrenalectomy with amino-
. glutethimide and dexamethasone is almost as 
effective as surgical adrenalectomy and does 
not preclude a response to surgical adrenal-
ectomy when tumor again progresses. A sche-
matic flow sheet to indicate serial treatment 
measures for advanced disease is shown in 
Table 11. 
The presence of extensive long bone me-
tastases or vertebral destruction should be han-
dled with radiotherapy to as small an area as 
possible. Some cases may require prophylatic 
internal fixation of the femur or humerus. 
Prompt laminectomy and decompression of the 
spinal cord in epidural tumors or vertebral col-
lapse is always worthwhile . Chemotherapy 
rather than hormonal therapy will almost always 
be required in such cases because of ttie need 
for rapid control of the disease to ensure contin-
ued ambulation. 
CNS involvement can frequently be han-
dled with moderate doses of radiation to the 
whole brain (3000 rads in 1 0 fractions), but 
meningeal involvement may also require intra-
thecal Methotrexate administration. 
Liver metastases, extensive visceral in-
TABLE 12 
Tenets of Breast Cancer Management 
1 . Make long-term plans for the management of the patient 
at the onset. 
2. Preserve or restore mobility and CNS function. 
3. Treatment of painful lesions is virtually always of benefit. 
4. Start treatment for local recurrences or systemic disease 
early; do not delay. 
5. Neither despair nor hold out unrealistic promise of cure. 
Hope is warranted by the facts . 
-104 / SMITH: BREAST CANCER: AN UPDATE 
Estrogen rebound 
Androgen 
Androgen rebound 
Antiestrogen 
Progesterone or Corticosteroid 
Chemotherapy 
volvement, bone marrow, or interstitial pulmo-
nary involvement present almost insur-
mountable management problems. However, 
some patients with liver metastases and marked 
liver dysfunction respond to cytotoxic drugs and 
these should be instituted . When the situation is 
desperate , doxorubicin containing regimens 
with their higher initial response rate are the cur-
rent choice. Extensive involvement of more than 
one organ requires cytotoxic drugs for systemic 
effect and radiation of painful or obstructing 
masses of tumor. 
Corticosteroids provide some short-term 
palliation of the patient with interstitial pulmo-
nary involvement. When bone marrow in-
volvement with persistent low blood counts pre-
cludes full doses of multiple drugs administered 
on the usual time schedules, reduction of doses 
and/or the number of drugs may still provide 
some means of control . 
Some general tenets of management of 
the patient with breast cancer are summarized 
in Table 12 . In all cases the most critical aspect 
of management is the close support of the pa-
tient by an understanding and sympathetic phy-
sician. 
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